Rifampicin Soft Capsules

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Rifampicin has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis. Bacteria have cross-resistance to rifamycin antibiotics. Rifampicin binds firmly to the β-subunit of DNA-dependent RNA polymerase, inhibiting the synthesis of bacterial RNA and preventing the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein.

Chemical name: 3-[[(4-methyl-1-piperazinyl)imino]methyl]-rifamycin. Molecular weight: C43H58N4O12

This product is in the form of capsules.

This product is used for the initial and retreatment treatment of various tuberculosis, including the treatment of tuberculous meningitis, and can reduce the development of drug resistance of Mycobacterium tuberculosis.

Oral administration: 3 to 6 capsules at a time, 1 to 2 times a day or as directed by a doctor.

1. Gastrointestinal reactions: The most common reactions. Gastrointestinal reactions such as anorexia, nausea, vomiting, upper abdominal discomfort, diarrhea, etc. may occur after oral administration of this product. The incidence rate is 1.7% to 4.0%, but they are all tolerable. 2. Hepatotoxicity is the main adverse reaction of this product, with an incidence rate of about 1%. In the first few weeks of treatment, a small number of patients may experience elevated serum aminotransferase, hepatomegaly, and jaundice. Most of them are asymptomatic transient elevations of serum aminotransferases, which can be recovered during the course of treatment. The elderly, alcoholics, malnourished people, those with pre-existing liver disease or other factors causing abnormal liver function are more likely to occur. 3. Allergic reactions: Flu-like syndrome may occasionally occur after high-dose intermittent therapy, manifested by chills, chills, fever, malaise, dyspnea, dizziness, drowsiness, and muscle pain.

1. Patients who are allergic to this product or rifamycin antibiotics are prohibited from using this product. 2. Patients with severe liver dysfunction and biliary obstruction are prohibited from using this product. 3. Pregnant women under 3 months old are prohibited from using this product. 4. Infants and young children are prohibited from using this product.

Precautions for children: The safety of this product for children under 5 years old has not been established. Use with caution in infants. Precautions for pregnancy and lactation: 1. Rifampicin can cross the placenta and has caused teratogenesis in animal experiments. Although there are no reports of teratogenesis in humans, there is currently insufficient information to show that it can be safely used during pregnancy. Pregnant women under three months old are prohibited from using this product. Pregnant women over three months old should use this product with caution. 2. Rifampicin can be excreted in breast milk. Lactating women should fully weigh the pros and cons before deciding whether to use this product. Precautions for the elderly: Elderly patients have decreased liver function and the dosage should be reduced as appropriate.

1. Drinking alcohol can increase the incidence of rifampicin hepatotoxicity and increase the metabolism of rifampicin. The rifampicin dose needs to be adjusted, and the patient should be closely observed for the occurrence of hepatotoxicity. 2. Para-aminosalicylate can affect the absorption of this product, resulting in a decrease in its blood concentration; if combined use is necessary, the two should be taken at least 6 hours apart. 3. The risk of hepatotoxicity increases when this product is used in combination with isoniazid, especially in patients with pre-existing liver damage and patients with rapid acetylation of isoniazid. 4. The combination of rifampicin and ethionamide can aggravate its adverse reactions. 5. Chlorphenazine can reduce the absorption of rifampicin, delay the peak time and prolong the half-life. 6. The combination of rifampicin with miconazole or ketoconazole can reduce the blood concentrations of the latter two, so this product should not be used in combination with imidazoles. 7. Adrenal cortical hormones (glucocorticoids, mineralocorticoids

Keep sealed.

90mg

24 months

Inner Mongolia Haitian Pharmaceutical Co., Ltd.

• Founded in:

  2017-12-07

• Address:

  No. 6, Xingong 2nd Road, Fourth Committee, Dongjiao Office, Horqin District, Tongliao City, Inner Mongolia Autonomous Region (east of Xingong 2nd Road, south of Mingren Street)

• Tax NO.:

  91150502MA0NNE3M0P

• Registered Funds:

  20 million yuan

• Email:

  Log in to view